Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
FE
Femasys Inc. Common Stock
FEMY
Mkt Cap
$13.9M
Volume
58.29K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
FE
FEMY
FE
Femasys Inc. Common Stock
FEMY
News
·
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
Mkt Cap
$13.8M
Volume
58.29K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
Femasys Inc. announced it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States, including prominent academic centers like Baylor Research Institute and Columbia University Medical Center. The expansion, enabled by August 2026 financing, demonstrates progress in the company's U.S. regulatory strategy for FDA approval of FemBloc, a non-surgical permanent birth control solution already approved in Europe, UK, and New Zealand.
GlobeNewswire Inc. · Oct 14, 2026
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
Femasys Inc. (NASDAQ: FEMY) announced CE Mark approval for its FemHSG™ Catheter, designed to support fertility diagnosis procedures when used with the FemVue device. The approval expands the company's fertility portfolio in Europe through commercial partners. The catheter features a small-profile design to accommodate varying uterine cavity sizes and enables comprehensive ultrasound-based diagnostic assessment of the uterine cavity and fallopian tubes.
GlobeNewswire Inc. · May 13, 2026
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Femasys Inc. announced a partnership with Refuah Health Center to expand access to FemaSeed, its intratubal insemination product, as a first-line infertility treatment in community-based care settings. The partnership aims to strengthen Femasys' commercial footprint and accelerate adoption of FemaSeed, which has demonstrated over double the pregnancy rates of traditional IUI in clinical trials.
GlobeNewswire Inc. · Jan 13, 2026
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
Femasys will showcase its FemaSeed Intratubal Insemination technology at the ASRM 2025 Scientific Congress, highlighting a fertility solution that offers higher pregnancy rates compared to traditional intrauterine insemination (IUI).
GlobeNewswire Inc. · Oct 16, 2025
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
Femasys introduces a new FemSperm Insemination Prep Kit to enable gynecologists to perform FemaSeed Intratubal Insemination, aiming to make fertility treatments more accessible and provide an alternative to IVF.
GlobeNewswire Inc. · Sep 11, 2025
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
Femasys Inc. announced a public offering of up to 22,184,586 shares of common stock and warrants, expecting to raise approximately $8.0 million to fund commercial expansion, product development, and corporate purposes.
GlobeNewswire Inc. · Aug 26, 2025
Femasys Revenue Jumps 85 Percent in Q2
Femasys reported 84.8% revenue growth in Q2 2025, achieving key regulatory approvals in Europe and Asia-Pacific, but faces potential cash constraints with limited runway into early Q4 2025.
The Motley Fool · Aug 8, 2025
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Femasys Inc. announced plans for a public offering of common stock and a concurrent private placement. The company intends to use the proceeds for expansion, product development, and general corporate purposes.
Benzinga · May 29, 2025
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its products Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its products
GlobeNewswire Inc. · Jun 27, 2024
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
Lee-Sepsick Discussed Company’s FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis Lee-Sepsick Discussed Company’s FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis
GlobeNewswire Inc. · May 17, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
FE
FEMY
Femasys Inc. Common Stock
Buy
Sell
Market
Limit
Soon
FEMY
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any FEMY yet.
Related Tickers
Earnings